| Parameter | RFC | FC | Incremental |
| --- | --- | --- | --- |
| Mean life years | 9.39 | 9.13 | 0.26 |
| Mean life years PFS | 4.25 | 3.03 | 1.23 |
| Mean life years progression | 5.14 | 6.11 | -0.97 |
| Mean QALYs | 5.40 | 5.06 | 0.34 |
| Mean QALYs PFS | 3.07 | 2.25 | 0.82 |
| Mean QALYs progression | 2.33 | 2.81 | -0.49 |
| Mean total costs | £ 26358 | £ 15892 | £ 10465 |
| Mean costs of PFS | £ 18875 | £ 6854 | £ 12021 |
| Mean costs of progression | £ 7483 | £ 9038 | £ -1556 |
| Cost per life year gained |  |  | £ 40474 |
| Cost per QALY gained |  |  | £ 30920 |
| FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; QALY, quality-adjusted life year. | | | |